CompletedPhase 1

Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella

Egypt70 participantsStarted 2023-10-30

Plain-language summary

The aim of the study is to evaluate the role of addition of Acetyl cysteine in the management of VAP induced by carbapenem resistant klebsiella. The primary outcome indicator is the change in modified clinical pulmonary infection score. The secondary outcome indicator is duration of mechanical ventilation.

Who can participate

Age range21 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are mechanically ventilated * Age from 21 to 65 * Both sexes. Exclusion Criteria: * Patient guardians who refuse the consent • Hypersensitivity to acetyl Cysteine. * Extrapulmonary infection. * Cardiac patient with chronic heart failure * Patient with lung diseases (tumors, tuberculosis, ,Chronic Obstructive Pulmonary Disease, Bronchiectasis and lung fibrosis) * Severe immunosuppression (total leucocyte \< 1000 mm3 or neutrophil \< 500 cell/mm3. * Patients on steroid or immunosuppressive drugs.

What they're measuring

Improvement of clinical pulmonary infection score.

Timeframe: 14 days

Trial details

NCT IDNCT07097727

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-30

View on ClinicalTrials.gov More Ventilator Associated Pneumonia ( VAP) trials